Metabolic Effects of a Conversion from Rosiglitazone to Pioglitazone in Native American Patients with Type 2 Diabetes

Sparkman, Jodi; Stroup, Jeffrey S.; Schupbach, Ryan; Carnahan, Ryan M.

doi:10.1080/08998280.2007.11928321

Cited by 3 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant changes occurred in body weight, body mass index, fasting glucose, HbA 1c , BP, or liver function tests. [51] Furthermore, 1 year of treatment with pioglitazone in combination with glimepiride was associated with significantly reduced plasma lipoprotein-a levels, compared with the rosiglitazone combination. [52] In another study, a switch from rosiglitazone to pioglitazone was associated with significant improvements in fasting plasma glucose levels (from 7.8 to 6.3 mmol L; p = 0.005) and HbA 1c (from 7.2 to 6.8%; [55-51 mmol mol]; p = 0.0001).…”

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 96%

“…Furthermore, in a retrospective analysis, the metabolic changes after the switch from rosiglitazone to pioglitazone were evaluated in 34 Native Americans with T2DM. [51] Patients receiving rosiglitazone 2 or 4 mg day were switched to pioglitazone 15 mg day, those receiving rosiglitazone 8 mg day were converted to pioglitazone 30 mg day, and patients receiving rosiglitazone 4 mg twice daily were switched to pioglitazone 45 mg day. After the change from rosiglitazone to pioglitazone and a median follow-up of 145 days, significant decreases in the levels of TC (-10.1%), LDL-C (-11.7%), and TG (-15.3%) were reported, as well as a non-significant increase in HDL-C (+6.4%).…”

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 99%

“…After the change from rosiglitazone to pioglitazone and a median follow-up of 145 days, significant decreases in the levels of TC (-10.1%), LDL-C (-11.7%), and TG (-15.3%) were reported, as well as a non-significant increase in HDL-C (+6.4%). [51] Significantly, more patients achieved LDL-C and TG target goals when taking pioglitazone than when taking rosiglitazone. No significant changes occurred in body weight, body mass index, fasting glucose, HbA 1c , BP, or liver function tests.…”

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 99%

See 2 more Smart Citations

Pioglitazone is a Valid Alternative to Rosiglitazone

Derosa

2011

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good glycemic control in patients with T2DM. Despite their efficacy, there was increasing concern regarding the potential of an increased cardiovascular risk with rosiglitazone. This resulted in the suspension of rosiglitazone from the European market by the European Medicines Agency in September 2010. This article focuses on the various steps that led to this important decision, and discusses a possible alternative for the treatment of patients receiving rosiglitazone.

show abstract

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 96%

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 99%

Section: Switching From Rosiglitazone To Pioglitazone: a Valid Option?mentioning

confidence: 99%

See 1 more Smart Citation

Pioglitazone is a Valid Alternative to Rosiglitazone

Derosa

2011

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

show abstract

“…24,25 Although both thiazolidinediones affect lipid parameters, their effects differ considerably. [28][29][30][31][32][33] Research indicates that pioglitazone may weakly activate PPAR-α receptors for beneficial lipemic responses, but information is not available regarding the effect of rosiglitazone on this receptor. 34 In a recent clinical trial, serum lipoprotein concentrations and particle size were compared between maximum doses of rosiglitazone or pioglitazone.…”

Section: Thiazolidinedionesmentioning

confidence: 99%

Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes

Blake

Sease

2009

Journal of Pharmacy Technology

View full text Add to dashboard Cite

To evaluate the effect of diabetes medications on the risk of cardiovascular disease and surrogate markers.Data Sources: Literature was accessed through MEDLINE (1950-July 2008 and PubMed using multiple terms for diabetes, cardiovascular risk, surrogate markers, and diabetes medications. In addition, reference citations from publications were reviewed.Study Selection and Data Extraction: English-language articles that met the above criteria, with clinical relevance, were evaluated.Data Synthesis: Evidence regarding the effect of diabetes medications on cardiovascular risk is sparse, with information on their effects on surrogate markers more widely available. Recent evidence demonstrates that glycemic control alone may not reduce the risk of macrovascular events. Multiple trials were reviewed to determine the effect of diabetes medications on this risk, as well as the effect on surrogate markers (eg, blood pressure, cholesterol, body weight). Metformin and acarbose demonstrated significant reductions in macrovascular events, including myocardial infarction. Data regarding sulfonylureas, thiazolidinediones, and insulin are conflicting. Pioglitazone may reduce cardiovascular events, except heart failure, whereas rosiglitazone may increase these events. Until direct evidence can be obtained, the full effect of diabetes medications on cardiovascular risk is unknown. Conclusions:Current literature provides little support that diabetes medications may lower the risk of cardiovascular events while some agents may increase this risk. Of the drugs available, metformin may be the least detrimental. Current literature regarding other diabetes medications provides conflicting results on their effect on cardiovascular outcomes. In the meantime, practitioners should treat all targets of cardiovascular risk in patients with diabetes.

show abstract

“…A number of clinical trials had demonstrated the lipid modifying superiority of pioglitazone over rosiglitazone, [5][6][7][8][9][10] which might be a factor in the differing CV outcomes between the two drugs, and the opportunity was taken to observe whether the previous international clinical trial data translated into improvement in lipid profiles upon switching in a normal clinical environment setting in the UK.…”

Section: Introductionmentioning

confidence: 99%

Changes in lipid parameters in patients with type 2 diabetes following a switch from rosiglitazone to pioglitazone in primary and secondary care: a prospective, descriptive study

Triay

Raghavan

Day

et al. 2011

Diabetes & Vascular Disease

View full text Add to dashboard Cite

M ounting evidence for increased cardiovascular risk being associated with rosiglitazone had led to Weston Health Trust to begin switching patients to the alternative thiazolidenedione, pioglitazone, at the end of 2007. The opportunity was taken to audit the lipidaemic and glycaemic results of these patients pre-and post-switch. In this predominantly elderly population (median ages: male 66 years; female 72), all markers of lipidaemia and glycaemia significantly improved over 12 weeks. Median changes from baseline to post-switch were: Total cholesterol from 4.0 mmol/L to 3.9 mmol/L; LDL-C from 2.3 mmol/L to 2.1 mmol/L; triglycerides from 1.5 mmol/L to 1.2 mmol/L; HDL-C rose 9% from 1.1 mmol/L to 1.2 mmol/L; non-HDL cholesterol fell 3.0 mmol/L to 2.7 mmol/L and ApoB fell from 0.73g/L to 0.62g/L. Glycaemic parameters also improved, with glycated haemoglobin A 1c dropping from 7.2% to 6.2% and fasting plasma glucose reducing from 7.7 mmol/L to 6.4 mmol/L. These results increased the percentage of patients achieving current guideline targets for all measured lipidaemic and glycaemic parameters. Br J Diabetes Vasc Dis 2011:31-37.

show abstract

Metabolic Effects of a Conversion from Rosiglitazone to Pioglitazone in Native American Patients with Type 2 Diabetes

Cited by 3 publications

References 28 publications

Pioglitazone is a Valid Alternative to Rosiglitazone

Pioglitazone is a Valid Alternative to Rosiglitazone

Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes

Changes in lipid parameters in patients with type 2 diabetes following a switch from rosiglitazone to pioglitazone in primary and secondary care: a prospective, descriptive study

Contact Info

Product

Resources

About